PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Autor:	Lantuejoul S; Centre Léon Bérard Unicancer, Lyon, France; Université Grenoble Alpes, Grenoble, France., Sound-Tsao M; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Cooper WA; Royal Prince Alfred Hospital, Camperdown, Australia., Girard N; Institut Curie, Paris, and Université Claude Bernard, Lyon, France., Hirsch FR; Center for Thoracic Oncology, The Tisch Cancer Institute, New York, New York; Ichan School of Medicine, Mount Sinai Health System, New York, New York., Roden AC; Mayo Clinic, Rochester, Minnesota., Lopez-Rios F; Pathology-Laboratorio de Dianas Terapeuticas, HM Hospitales, Spain., Jain D; All India Institute of Medical Sciences, New Delhi, India., Chou TY; Taipei Veterans General Hospital, Taipei, Taiwan., Motoi N; National Cancer Center Hospital, Tokyo, Japan., Kerr KM; Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom., Yatabe Y; National Cancer Center Hospital, Tokyo, Japan., Brambilla E; Université Grenoble Alpes, Grenoble, France., Longshore J; Carolinas Pathology Group, Charlotte, North Carolina., Papotti M; University of Turin, Turin, Italy., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Thunnissen E; Department of Pathology, VU University Medical Center, Amsterdam, Netherlands., Rekhtman N; Memorial Sloan Kettering Cancer Center, New York, New York., Borczuk A; Weill Cornell Medicine, New York, New York., Bubendorf L; Institute of Pathology, University of Basel, Basel, Switzerland., Minami Y; Ibarakihigashi National Hospital, Tokai, Japan., Beasley MB; Ichan School of Medicine, Mount Sinai Health System, New York, New York., Botling J; Uppsala University Hospital, Uppsala, Sweden., Chen G; Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China., Chung JH; Seoul National University Bundang Hospital, Seoul, South Korea., Dacic S; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Hwang D; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Lin D; Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China., Moreira A; New York University School of Medicine, New York, New York., Nicholson AG; Royal Brompton and Harefield NHS Foundation Trust, London, and National Heart and Lung Institute, Imperial College, United Kingdom., Noguchi M; University of Tsukuba, Tsukuba, Japan., Pelosi G; University of Milan and IRCCS MultiMedica, Milan, Italy., Poleri C; Office of Pathology Consultants, Buenos Aires, Argentina., Travis W; Memorial Sloan Kettering Cancer Center, New York, New York., Yoshida A; National Cancer Center Hospital, Tokyo, Japan., Daigneault JB; International Association for the Study of Lung Cancer, Aurora, Colorado., Wistuba II; The University of Texas MD Anderson Cancer Center, Houston, Texas., Mino-Kenudson M; Department of Pathology, Harvard Medical School, Boston, Massachusetts; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: mminokenudson@partners.org.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Apr; Vol. 15 (4), pp. 499-519. Date of Electronic Publication: 2019 Dec 20.
DOI:	10.1016/j.jtho.2019.12.107
Abstrakt:	The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (ICs) by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms, and many laboratories have set up in-house or laboratory-developed tests that are more affordable than the generally expensive clinical trial-validated assays. Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. Because many articles have been published since the issue of the IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, this review by the IASLC Pathology Committee provides updates on the indications of ICIs for lung cancer in 2019 and discusses important considerations on preanalytical, analytical, and postanalytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance, and training. (Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu